Apogee Therapeutics, Inc. (APGE)

Apogee Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022
Selling, General & Admin	24.58	2.94
Research & Development	68.42	27.79
Operating Expenses	93	30.73
Operating Income	-93	-30.73
Other Expense / Income	-9.02	9.06
Pretax Income	-83.99	-39.79
Net Income	-83.99	-39.79
Shares Outstanding (Basic)	25	2
Shares Outstanding (Diluted)	25	2
Shares Change	915.57%	-
EPS (Basic)	-3.36	-16.16
EPS (Diluted)	-3.36	-16.16
Free Cash Flow	-74.93	-16.43
Free Cash Flow Per Share	-3.00	-6.67
EBITDA	-83.9	-39.79
Depreciation & Amortization	0.09	0
EBIT	-83.99	-39.79

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).